Evidence map›Paper›PMID 39555114›Full record

ArticleClinical Medicine Insights. Oncology2024

Platelet-Rich Plasma Inhibits Breast Cancer Proliferation.

Chao Han, Caiping Chen, Ning Lu, Li Xue, Dan Xing, Wanxin Wu, Wang Li, Xiang Lu

Abstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao HanDepartment of Breast Surgery, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Caiping ChenDepartment of Breast Surgery, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Ning LuDepartment of Pathology, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Li XueDepartment of Breast Surgery, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Dan XingDepartment of Breast Surgery, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Wanxin WuDepartment of Pathology, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Wang LiDepartment of Breast Surgery, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Xiang LuDepartment of Breast Surgery, Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.ORCID https://orcid.org/0000-0002-7906-6701

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Platelet-rich plasma (PRP) helps promote wound healing, but it is unclear whether it stimulates breast cancer cell proliferation, which restricts its application in breast cancer patients. This article explored the effect of PRP on breast cancer cell proliferation through preclinical experiments. Method: We cultivated MDA-MB-231 breast cancer cells with PRP in vitro. Subsequently, we employed Cell Counting Kit-8 (CCK-8) assays to assess their proliferation ability, wound healing assays to evaluate their migration ability, and Transwell assays to detect their invasion ability. Mouse breast cancer 4T1 cells were subcutaneously inoculated into nude mice. After tumor formation, PRP was injected around each tumor. Tumor size was measured. After 15 days, the tumors were surgically removed. Immunohistochemistry was used to detect key proteins involved in proliferation and apoptosis. Results: PRP inhibited the proliferation, migration, and invasion of MDA-MB-231 in vitro. After PRP was injected around tumors in nude mice, tumor growth slowed, Ki67 and phospho-histone H3 (pHH3) expression decreased, and Caspase 3 and Poly (adenosine diphosphate-ribose) polymerase 1 (PARP1) expression increased. Conclusion: The PRP inhibits the proliferation of breast cancer MDA-MB-231 and 4T1 cells.

Indexed as

Apoptosisbreast cancermolecular oncologyplatelet-rich plasmapreclinical studiesproliferationtranslational researchtumor safety

Identifiers

PMID39555114
PMCPMC11569502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.